Treatment of patients with systemic lupus erythematosus without glucocorticoids – myth or reality?
https://doi.org/10.14412/1996-7012-2022-1-77-83
Abstract
Glucocorticoids (GC) currently remain one of the most important components of the treatment of systemic lupus erythematosus (SLE). However, prolonged use of GC inevitably leads to the development of irreversible organ damage. It has been proven that the use of biological diseasemodifying antirheumatic drugs that block key pathogenetic pathways of SLE has an advantage in patients with high disease activity and dependence on the use of medium and high doses of GC.
Three clinical cases are presented in which patients with active SLE were treated with rituximab and belimumab without the use of oral GC.
About the Authors
S. K. Soloviev
JSC Group of companies MEDSI
Russian Federation
Russian Federation
3A, Gruzinskiy pereulok, Moscow 123056
A. A. Mesnyankina
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
Anna Alexandrovna Mesnyankina
34A, Kashirskoe shosse, Moscow 115522
N. Yu. Nikishina
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
34A, Kashirskoe shosse, Moscow 115522
E. A. Aseeva
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
34A, Kashirskoe shosse, Moscow 115522
A. M. Lila
V.A. Nasonova Research Institute of Rheumatology; Department of Rheumatology, Russian Medical Academy of Continuing Professional Education
Russian Federation
Russian Federation
34A, Kashirskoe shosse, Moscow 115522
2/1, Barrikadnaya street, building 1, Moscow 125993
References
1. Nasonov EL, editor. Revmatologiya. Rossiiskie klinicheskie rekomendatsii [Rheumatology. Russian clinical guidelines]. Moscow: GEOTAR-Media; 2017.
2. Trager J, Ward MM. Mortality and causes of death in systemic lupus erythematosus. Curr Opin Rheumatol. 2001 Sep;13(5):345-51. doi: 10.1097/00002281-200109000-00002.
3. Stojan G, Petri M. Epidemiology of Systemic Lupus Erythematosus: an update. Curr Opin Rheumatol. 2018 Mar;30(2):144-50. doi: 10.1097/BOR.0000000000000480.
4. Solovyev SK, Aseeva EA, Nasonov EL, et al. Possibilities and prospects for glucocorticoid withdrawal in systemic lupus erythematosus. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2020;14(1):6-11. (In Russ.). doi: 10.14412/1996-7012-2020-1-6-11
5. Gladman DD, Urowitz MB, Rahman P, et al. Accrual of organ damage over time in patients with systemic lupus erythematosus. J Rheumatol. 2003 Sep;30(9):1955-9.
6. Zonana-Nacach A, Barr SG, Magder LS, et al. Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum. 2000 Aug;43(8):1801-8. doi: 10.1002/1529-0131(200008)43:8<1801:: AID-ANR16>3.0.CO;2-O.
7. Dixon WG, Abrahamowicz M, Beauchamp ME, et al. Immediate and delayed impact of oral glucocorticoid therapy on risk of serious infection in older patients with rheumatoid arthritis: a nested case-control analysis. Ann Rheum Dis. 2012 Jul;71(7):1128-33. doi: 10.1136/annrheumdis-2011-200702. Epub 2012 Jan 12.
8. Bruce IN. 'Not only… but also': factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosus. Rheumatology (Oxford). 2005 Dec;44(12):1492-502. doi: 10.1093/rheumatology/kei142. Epub 2005 Oct 18.
9. Bhangle SD, Kramer N, Rosenstein ED. Corticosteroid-induced neuropsychiatric disorders: review and contrast with neurosychiatric lupus. Rheumatol Int. 2013 Aug;33(8): 1923-32. doi: 10.1007/s00296-013-2750-z. Epub 2013 Apr 16.
10. Carter EE, Barr SG, Clarke AE. The global burden of SLE: prevalence, health disparities and socioeconomic impact. Nat Rev Rheumatol. 2016 Oct;12(10):605-20. doi: 10.1038/nrrheum.2016.137. Epub 2016 Aug 25.
11. Barber MRW, Clarke AE. Socioeconomic consequences of systemic lupus erythematosus. Curr Opin Rheumatol. 2017 Sep;29(5): 480-5. doi: 10.1097/BOR.0000000000000416.
12. Sheane J, Urowitz MB, Gladman DD. Atherosclerosis in Systemic Lupus Erythematosus – Epidemiology, Risk Factors, Subclinical Assessment and Future Study. Rheumatol Curr Res. 2013;S5. doi: 10.4172/2161-1149.S5-004
13. Nikpour M, Gladman DD, Urowitz MB. Premature coronary heart disease in systemic lupus erythematosus: what risk factors do we understand? Lupus. 2013 Oct;22(12):1243-50. doi: 10.1177/0961203313493031.
14. Popkova TV, Panafidina TA, Solovyev SK. According to the 2019 updated European League Against Rheumatism (EULAR) recommendations for the treatment of systemic lupus erythematosus: debatable issues and comments. Nauchno-prakticheskaya revmatologiya. 2019;57(5):496-510. (In Russ.). doi: 10.14412/1995-4484-2019-496-510
15. Tsanyan ME, Soloviev SK, Torgashina AV, et al. Rituximab treatment efficacy in patients with systemic lupus erythematosus refractory to standard therapy in the long-term followup. Nauchno-prakticheskaya revmatologiya. 2014;52(2):159-68. (In Russ.). doi:10.14412/1995-4484-2014-159-168
16. Aseeva EA, Soloviev SK, Mesnyankina AA, et al. Results of an observational prospective study of the efficacy and safety of belimumab (benlysta®) in systemic lupus erythematosus in real clinical practice. Nauchno-prakticheskaya revmatologiya. 2016;54(1):31-7. (In Russ.).
17. Aseeva EA, Soloviev SK, Mesnyankina AA, et al. Experience with belimumab in patients with systemic lupus erythematosus. Nauchnoprakticheskaya revmatologiya. 2015;53(3): 329-35. (In Russ.).
18. Kraaij T, Kamerling SWA, de Rooij ENM, et al. The NET-effect of combining rituximab with belimumab in severe systemic lupus erythematosus. J Autoimmun. 2018 Jul;91:45-54. doi: 10.1016/j.jaut.2018.03.003. Epub 2018 Apr 7.
19. Kraaij T, Arends EJ, van Dam LS, et al. Long-term effects of combined B-cell immunomodulation with rituximab and belimumab in severe, refractory systemic lupus erythematosus: 2-year results. Nephrol Dial Transplant. 2021 Jul 23;36(8):1474-83. doi: 10.1093/ndt/gfaa117.
20. https://clinicaltrials.gov/ct2/show/NCT02260934
21. Mesnyankina AA, Solovyev SK, Nikishina NYu, et al. Sequential therapy with rituximab and belimumab in patients with systemic lupus erythematosus. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2020;14(4): 31-8.(In Russ.). doi:10.14412/1996-7012-2020-4-31-38
22. Zen M, Gatto M, Nalotto L, et al. The management of systemic lupus Erythematosus (SLE) patients in Remission. Isr Med Assoc J. 2017 Jul;19(7):454-8.
23. Urowitz MB, Feletar M, Bruce IN, et al. Prolonged remission in systemic lupus erythematosus. J Rheumatol. 2005 Aug;32(8):1467-72.
24. Moroni G, Longhi S, Giglio E, et al. What happens after complete withdrawal of therapy in patients with lupus nephritis. Clin Exp Rheumatol. Jul-Aug 2013;31(4 Suppl 78): S75-81. Epub 2013 Oct 4.
25. Condon MB, Ashby D, Pepper RJ, et al. Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Ann Rheum Dis. 2013 Aug;72(8):1280-6. doi: 10.1136/annrheumdis-2012-202844. Epub 2013 Jun 5.
26. Gracia-Tello B, Ezeonyeji A, Isenberg D. The use of rituximab in newly diagnosed patients with systemic lupus erythematosus: longterm steroid saving capacity and clinical effectiveness. Lupus Sci Med. 2017 Feb 2;4(1): e000182. doi: 10.1136/lupus-2016-000182.eCollection 2017.
Review
For citations:
Soloviev SK, Mesnyankina AA, Nikishina NY, Aseeva EA, Lila AM. Treatment of patients with systemic lupus erythematosus without glucocorticoids – myth or reality? Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2022;16(1):77-83. (In Russ.) https://doi.org/10.14412/1996-7012-2022-1-77-83
Views:
1078
Email this article 